Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Therapeutic BCG Vaccines Market Size Forecast: How Big Could The Market Get By 2030?
The therapeutic bcg vaccines market has experienced substantial growth in recent years. It is projected to increase from $59.09 billion in 2025 to $62.77 billion in 2026, at a compound annual growth rate (CAGR) of 6.2%. This historical growth can be attributed to factors such as high tb prevalence, rising research in immunotherapy, limited vaccination coverage, various government health initiatives, and increased awareness of bcg benefits.
The therapeutic bcg vaccines market is poised for significant expansion in the coming years. Its size is predicted to reach $80.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.4%. This projected expansion during the forecast period is driven by factors such as the increasing demand for personalized vaccines, advancements in vaccine delivery technology, a heightened focus on immuno-oncology applications, the broadening scope of public health programs, and growing investments in biotech innovations. Prominent trends expected in the forecast period include the development of personalized BCG therapies, innovations in vaccine delivery methods, expanded research into TB immunotherapy, combination therapies utilizing BCG, and immunization programs funded by governments.
Get A Free Sample Report With In-Depth Market Insights:
Therapeutic BCG Vaccines Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The global increase in tuberculosis (TB) cases is set to drive the expansion of the therapeutic BCG vaccine market in the future. TB, an infectious and potentially hazardous disease, primarily affects the lungs and spreads through airborne bacterial droplets when infected individuals cough or sneeze. BCG vaccines stimulate the immune system to combat infection without causing TB, as they contain weakened germs. These vaccines consistently provide defense against severe forms of TB, including adolescent TB meningitis. By protecting against tuberculosis and aiding in the fight against infection, the application of therapeutic BCG vaccines has consequently risen. For example, a report from the UK Health Security Agency in February 2024 indicated a 10.7% rise in tuberculosis (TB) cases in England during 2023, reporting 4,850 cases versus 4,380 in 2022. This global increase in tuberculosis (TB) cases is, therefore, a primary driver for the expansion of the therapeutic BCG vaccine market.
Therapeutic BCG Vaccines Market Segmentation And Category Overview
The therapeutic bcg vaccines market covered in this report is segmented –
1) By Type: Therapy BCG, Other Types
2) By Demographics: Pediatrics, Adults
3) By End Use: Hospitals, Clinics, Other End Users
Therapeutic BCG Vaccines Market Innovation Trends Shaping Future Development
Major companies within the therapeutic BCG vaccine market are concentrating on developing innovative vaccines for potential therapeutic applications in diverse medical conditions, including BCG immunotherapy, with the goal of expanding their customer base and addressing growing patient needs. BCG (Bacillus Calmette-Guérin) immunotherapy refers to the application of the BCG vaccine as a form of immunotherapy for treating specific types of cancer, particularly bladder cancer. As an illustration, in July 2023, The Serum Institute of India, an India-based biotechnology and biopharmaceuticals company, obtained government approval to export its BCG vaccine to Canada for immunotherapeutic use in bladder cancer treatment. This live freeze-dried preparation, derived from an attenuated strain of Mycobacterium bovis (Bacillus Calmette Guerin), is available in 40 mg and 80 mg presentations. As a fundamental component of the therapy, the vaccine is administered directly into the bladder using a catheter, where it remains in the bladder lining for a specified duration. This targeted method seeks to effectively impact cancer cells while minimizing adverse effects on other parts of the body.
Therapeutic BCG Vaccines Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the therapeutic bcg vaccines market are Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, Bharat Biotech International Ltd., Shanghai Institute of Biological Products Co. Ltd., Instituto Butantan, BioCen, Panacea Biotec Ltd., Institute Pasteur de Tunis, Korean BCG Vaccine Institute
View The Full Therapeutic BCG Vaccines Market Report:
Therapeutic BCG Vaccines Market Geographic Spread And Regional Opportunities
Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2025. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
